The Patent Finder

Y-Biologics Inc.

12 patents currently held · Updated Nov 15, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 2 name spellings.

0
Ending by 2030
Feb 2037
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Apr 22, 2027
    The maintenance fee for Composition for Preventing or Treating Fatty Liver or Insulin Resistance Syndrome Including Extracellular Domain of Delta-Like 1 Homolog (US 10,448,662) comes due Apr 22, 2027. Unpaid by Oct 22, 2027, it lapses early.
  • 2 fees due Oct 2 to 28, 2027 · next Oct 2
  • 1 fee due Nov 5, 2027
    The maintenance fee for Cell engaging binding molecules (US 10,640,576) comes due Nov 5, 2027. Unpaid by May 5, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 10,448,662Composition for Preventing or Treating Fatty Liver or Insulin Resistance Syndrome Including Extracellular Domain of Delta-Like 1 Homolog
In force
 · High confidence
In forceHigh confidence
US 10,919,966Antibody to programmed death-ligand 1 (PD-L1) and use thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,306,141Antibody against human DLK1 and use thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,248,048Antibody to programmed cell death 1 (PD-1) and use thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,633,458Cell engaging binding molecules
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,640,576Cell engaging binding molecules
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,654,944Cell engaging binding molecules
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,836,833Cell engaging binding molecules
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,945,864Monoclonal antibody specifically binding to LAG-3 and use thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 12,139,530Bispecific antibody specifically binding to IL-17A and TNF-α
In force
 · From the USPTO record
In forceFrom the USPTO record
10 of 12 patents shown.
Pro members see all 12.
Pro members: see all 12 patents
Also on record, not counted in the 12: 1 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

5 pending · 2 abandoned · 1 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited